Use of palivizumab in children with congenital heart disease.
出版信息
Paediatr Child Health. 2003 Dec;8(10):631-6. doi: 10.1093/pch/8.10.631.
Abstract
摘要
相似文献
1
Use of palivizumab in children with congenital heart disease.
Paediatr Child Health. 2003 Dec;8(10):631-6. doi: 10.1093/pch/8.10.631.
2
Palivizumab in congenital heart disease: should international guidelines be revised?
Expert Opin Biol Ther. 2007 Nov;7(11):1615-20. doi: 10.1517/14712598.7.11.1615.
3
Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.
Paediatr Child Health. 2006 Jan;11(1):19-23.
4
Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
Expert Opin Biol Ther. 2007 Sep;7(9):1471-80. doi: 10.1517/14712598.7.9.1471.
5
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
J Pediatr. 2003 Oct;143(4):532-40. doi: 10.1067/s0022-3476(03)00454-2.
6
Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.
BMC Pediatr. 2019 Aug 28;19(1):299. doi: 10.1186/s12887-019-1681-6.
7
Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
Can J Cardiol. 2007 May 1;23(6):463-6. doi: 10.1016/s0828-282x(07)70785-7.
8
Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease.
Pediatr Int. 2005 Aug;47(4):397-403. doi: 10.1111/j.1442-200x.2005.02089.x.
9
A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
Pediatr Res. 2011 Aug;70(2):186-91. doi: 10.1203/PDR.0b013e318220a553.
10
Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study.
Pediatr Pulmonol. 2015 Oct;50(10):1025-32. doi: 10.1002/ppul.23102. Epub 2014 Aug 25.
引用本文的文献
1
Addressing immunization gaps in children with congenital heart disease - a narrative review.
Med Pharm Rep. 2025 Jul;98(3):283-289. doi: 10.15386/mpr-2814. Epub 2025 Jul 30.
2
Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017.
Arch Dis Child. 2021 Feb;106(2):173-179. doi: 10.1136/archdischild-2020-319472. Epub 2020 Aug 28.
3
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).
Ital J Pediatr. 2015 Dec 15;41:97. doi: 10.1186/s13052-015-0203-x.
4
Preventing hospitalizations for respiratory syncytial virus infection.
Paediatr Child Health. 2015 Aug-Sep;20(6):321-33. doi: 10.1093/pch/20.6.321.
5
Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.
Eur J Pediatr. 2012 May;171(5):833-41. doi: 10.1007/s00431-011-1654-8. Epub 2011 Dec 28.
6
A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.
Can Respir J. 2011 Mar-Apr;18(2):e10-9. doi: 10.1155/2011/493056.
7
Prevention of respiratory syncytial virus infection.
Paediatr Child Health. 2009 Oct;14(8):521-32. doi: 10.1093/pch/14.8.521.
8
A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection.
BMC Infect Dis. 2009 Jul 5;9:106. doi: 10.1186/1471-2334-9-106.
9
Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.
Paediatr Child Health. 2006 Jan;11(1):19-23.
10
Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
Can J Cardiol. 2007 May 1;23(6):463-6. doi: 10.1016/s0828-282x(07)70785-7.
本文引用的文献
1
Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?
Paediatr Child Health. 1998 Nov;3(6):402-4. doi: 10.1093/pch/3.6.402.
2
Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.
Paediatr Child Health. 1999 Oct;4(7):474-89.
3
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
J Pediatr. 2003 Oct;143(4):532-40. doi: 10.1067/s0022-3476(03)00454-2.
4
Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.
Drug Saf. 2003;26(4):283-91. doi: 10.2165/00002018-200326040-00005.
5
Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening.
Pediatr Cardiol. 2000 Sep-Oct;21(5):433-8. doi: 10.1007/s002460010103.
6
Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome.
Crit Care Med. 1999 Sep;27(9):1974-81. doi: 10.1097/00003246-199909000-00042.
7
Respiratory syncytial virus infection.
Lancet. 1999 Sep 4;354(9181):847-52. doi: 10.1016/S0140-6736(99)80040-3.
8
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.
J Pediatr. 1998 Oct;133(4):492-9. doi: 10.1016/s0022-3476(98)70056-3.
9
Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada Study.
Pediatrics. 1997 Dec;100(6):943-6. doi: 10.1542/peds.100.6.943.
10
PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease.
Pediatrics. 1997 Mar;99(3):E9. doi: 10.1542/peds.99.3.e9.
Zotero 插件